Plain-English translation of NCT07202078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a common antibiotic called trimethoprim-sulfamethoxazole (or doxycycline as an alternative) can prevent infections as well as immunoglobulin replacement therapy in people with blood cancers like myeloma, lymphoma, or leukemia. You would be randomly assigned to either take a daily antibiotic pill or receive immunoglobulin infusions every 4 weeks. The goal is to see if the simpler, daily antibiotic approach works just as well as the more involved immunoglobulin treatment.
Patients with certain blood cancers have weak immune systems and are at high risk for dangerous infections. Currently, immunoglobulin replacement is the standard way to prevent these infections, but it requires regular infusions and can be expensive. This trial wants to know if a simple, affordable daily antibiotic could protect patients just as effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to one of two groups: either take a daily antibiotic tablet by mouth, or receive immunoglobulin infusions through an IV every 4 weeks (or weekly injections under the skin if that's available at your center). You'll have regular clinic visits to monitor how well the treatment is working and to watch for any side effects or infections. The trial involves about 900 patients total, so you'll be part of a large study helping doctors understand the best way to protect people with blood cancers from serious infections.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Australia